.png){kind=icon}
.png){kind=icon}
Return
Challenges and opportunities of human iPSC-derived NK as “Off-the-shelf” cellular therapies
.png){kind=icon}
OA
AI
N
R
M
M
DOI：10.1186/s13046-025-03558-6.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The field of human induced pluripotent stem cell (hiPSC)-derived cell therapies is rapidly advancing, offering a promising “off-the-shelf” approach for treating both solid and hematologic malignancies. Among these, hiPSC-derived Natural Killer (NK) cell therapies have gained significant traction, with several currently in clinical trials and development. NK cell-based immunotherapy has emerged as a safe and effective strategy for patients with advanced leukemia, and ongoing research is focused on optimizing its accessibility, scalability, and efficacy. A key advantage of hiPSC-derived NK cells is their genetic susceptibility, allowing for targeted enhancements in fitness, metabolism, specificity, and cytotoxicity. This overcomes the donor-dependent variability that limits autologous and allogeneic NK cell therapies, which often struggle with expansion and functional consistency. Despite their promise, hiPSC-derived NK cells present unique manufacturing challenges, requiring precise optimization to ensure reproducibility, safety, and clinical-grade scalability. In this review, we will explore what we believe to be the most impactful genetic engineering strategies to enhance hiPSC-derived NK cell function. Additionally, we will also discuss the major hurdles challenging widespread clinical adoption, including licensing constraints, production yield, regulatory ambiguities, and the complexities of multi-step genetic engineering and safety validation. Finally, we will outline the emerging therapeutic pipelines from leading biotech companies, providing a valuable and up-to-date overview of the future landscape of hiPSC-derived NK cell therapy.
Keywords:
Human induced pluripotent stem cell
Natural killer
Genome editing
Chimeric antigen receptor
Cell therapy
Clinical trial
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
12.8
Papers:
4.4K
Citations:
2.9W
Organization
Cited Papers